tiprankstipranks
Callan JMB, Inc. (CJMB)
NASDAQ:CJMB
US Market
Want to see CJMB full AI Analyst Report?

Callan JMB, Inc. (CJMB) AI Stock Analysis

21 Followers

Top Page

CJMB

Callan JMB, Inc.

(NASDAQ:CJMB)

Select Model
Select Model
Select Model
Neutral 41 (OpenAI - 5.2)
Rating:41Neutral
Price Target:
$0.76
▼(-47.93% Downside)
Action:Reiterated
Date:05/20/26
The score is held down primarily by sharply weakened financial performance (deep losses, contracting revenue, and negative free cash flow) and bearish technicals (below key moving averages with negative MACD). A Nasdaq equity deficiency notice adds additional risk, while valuation data is not sufficiently meaningful to provide offsetting support.
Positive Factors
Low Leverage
Near-zero debt materially lowers interest burden and financial distress risk, giving the company breathing room while it addresses operating losses. This durable balance-sheet feature preserves flexibility to restructure, pursue contracts, or raise capital without heavy interest constraints.
Negative Factors
Deep Operating Losses
Extremely negative margins reflect persistent operating shortfalls that erode shareholder equity and limit reinvestment capacity. Sustained operating losses indicate structural issues in demand or cost structure that must be resolved to restore profitability and long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Near-zero debt materially lowers interest burden and financial distress risk, giving the company breathing room while it addresses operating losses. This durable balance-sheet feature preserves flexibility to restructure, pursue contracts, or raise capital without heavy interest constraints.
Read all positive factors

Callan JMB, Inc. (CJMB) vs. SPDR S&P 500 ETF (SPY)

Callan JMB, Inc. Business Overview & Revenue Model

Company Description
Callan JMB Inc., through its subsidiary, Coldchain Technology Services, LLC provides thermal management logistics solutions to the life sciences industry. It offers logistics solutions and services utilized for frozen shipping in the life sciences...

Callan JMB, Inc. Financial Statement Overview

Summary
Financials have deteriorated sharply: TTM net margin is ~-185% with very large operating losses, revenue is down meaningfully versus 2022–2023, and operating/free cash flow have turned negative. While gross profit remains positive and leverage is now essentially zero, the equity base has compressed materially (to about ~$1.6M), limiting flexibility and indicating ongoing value erosion.
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
24
Negative
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022
Income Statement
Total Revenue5.38M5.72M6.56M13.20M22.77M
Gross Profit1.92M2.10M2.56M5.65M9.45M
EBITDA-8.31M-7.81M-2.12M2.30M6.37M
Net Income-9.94M-7.97M-2.29M2.18M6.22M
Balance Sheet
Total Assets5.71M5.78M5.08M9.71M15.25M
Cash, Cash Equivalents and Short-Term Investments1.42M2.13M2.10M5.16M6.19M
Total Debt0.002.00M907.45K400.00K410.88K
Total Liabilities2.60M3.45M1.91M910.27K1.24M
Stockholders Equity1.60M2.33M3.17M8.80M14.01M
Cash Flow
Free Cash Flow-2.97M-5.16M494.19K6.51M8.94M
Operating Cash Flow-2.99M-4.55M540.35K7.00M9.36M
Investing Cash Flow-637.21K-616.90K-46.17K-490.02K-422.49K
Financing Cash Flow1.50M5.20M-3.55M-7.54M-4.57M

Callan JMB, Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.45
Price Trends
50DMA
4.34
Negative
100DMA
4.65
Negative
200DMA
Market Momentum
MACD
-0.26
Positive
RSI
29.52
Positive
STOCH
25.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CJMB, the sentiment is Negative. The current price of 1.45 is below the 20-day moving average (MA) of 3.85, below the 50-day MA of 4.34, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -0.26 indicates Positive momentum. The RSI at 29.52 is Positive, neither overbought nor oversold. The STOCH value of 25.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CJMB.

Callan JMB, Inc. Risk Analysis

Callan JMB, Inc. disclosed 45 risk factors in its most recent earnings report. Callan JMB, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Callan JMB, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
$9.06M8.98%39.03%-67.49%
65
Neutral
$2.17B12.193.79%4.94%3.15%1.96%
51
Neutral
$118.55M-1.28-440.71%
41
Neutral
$4.04M
* Real Estate Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CJMB
Callan JMB, Inc.
0.72
-4.35
-85.87%
SGLY
Singularity Future Technology
0.42
-0.50
-54.41%
ATXG
Addentax Group
4.26
-4.74
-52.67%
PSIG
PS International Group
7.71
4.96
180.36%
GVH
Globavend Holdings Ltd.
4.28
-301.72
-98.60%
NCEW
New Century Logistics (BVI) Ltd.
20.03
10.03
100.30%

Callan JMB, Inc. Corporate Events

Delistings and Listing ChangesRegulatory Filings and Compliance
Callan JMB Receives Nasdaq Deficiency Notice on Equity
Negative
Apr 10, 2026
On April 7, 2026, Callan JMB Inc. received a deficiency notice from Nasdaq stating that the company was no longer in compliance with the exchange’s requirement to maintain at least $2.5 million in stockholders’ equity for continued lis...
Private Placements and FinancingRegulatory Filings and Compliance
Callan JMB Amends Equity Purchase Agreement with Hexstone
Neutral
Mar 12, 2026
On March 10, 2026, Callan JMB Inc. amended its existing common stock purchase agreement with Hexstone Capital, LLC, extending the maturity date to April 1, 2027 and revising key pricing and trading terms governing future stock sales. The regular p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 20, 2026